| Name | Title | Contact Details |
|---|
BioMarin is a global pharmaceutical company focused on developing first-in-class and best-in-class therapeutics that provide meaningful advances to patients who live with serious and life-threatening rare genetic diseases. We remain steadfast to our original mission—to bring new treatments to market that will make a big impact on small patient populations. These patient populations are mostly children, suffering from diseases so rare, that the entire patient population can number as few as 1,000 people worldwide. These conditions are often inherited, difficult to diagnose, progressively debilitating, have few, if any, treatment options and are usually ignored. Time is critical to patients with rare diseases, and we strive to quickly develop important therapies for them. The efficiency and speed of our research, development, manufacturing, and commercial efforts is at the heart of our ability to urgently deliver therapies. Our track record of developing and commercializing new treatments has been significantly faster than the industry average and is a remarkable accomplishment that is ingrained in our culture. The company`s product portfolio comprises five marketed products and multiple clinical and pre-clinical product candidates.
Inform Genomics, Inc, is a privately held company that utilizes a proprietary technology platform to discover and develop genomic-based, precision medicine products that are designed to predict, with a high degree of accuracy, clinically important outcomes that assist physicians and their patients in making individualized medical decisions. Its lead development program is in oncology supportive care, with two major products currently in development--OnPART™ and HSCT/Mucositis™--designed not only to predict a patient's risk for developing common chemotherapy-related side effects, but also to assess a patient's willingness to tolerate those side effects. The Company's novel, IP-protected technology platform capitalizes on big data storage/memory and sophisticated cloud computing technologies. It consists of proprietary Bayesian networks and other advanced bioinformatic analytics combined with validated patient assessment tools. The Company's analytics discover interactions of genes and single nucleotide polymorphisms (SNPs) that can predict clinical outcomes. Inform Genomics' goal is to be a trusted partner to health care practitioners so that they, together with their patients, can make optimal health care choices based on an individual patient's needs and values.
Chiron Corporation was an American multinational biotechnology firm founded in 1981, based in Emeryville, California, that was acquired by Novartis on April 20, 2006.
Predictive Diagnostics is a Vacaville, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Kowa Research Institute is a Morrisville, NC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.